Medifast, Inc. shares are trading close to a resistance zone which currently limits any upside potential. We expect that this level will be broken due to the stock's technical chart pattern. Investors have an opportunity to buy the stock and target the $ 200.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company is in a robust financial situation considering its net cash and margin position.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Historically, the company has been releasing figures that are above expectations.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 95.62 USD
The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.